PHARMACOLOGICAL EVALUATION OF PIRACETAM AND VANADYL SULFATE ON EXPERIMENTALLY INDUCED CEREBRAL ISCHEMIA IN RATS
Objective: The aim of present study was designed to evaluate the combinatorial effect of piracetam and vanadyl sulfate on experimentally induced global cerebral ischemia in rats.
Methods: Piracetam (600 mg/kg, p. o.) and vanadyl sulfate (22.4 mg/kg, p. o.) were administered individually and also in combination before the induction of ischemia. Cerebral ischemia was induced by bilateral carotid artery (BCA) occlusion for 30 min followed by reperfusion 60 min.
Results: The antioxidant and non-antioxidant enzymatic levels were estimated along with histopathological studies. The concomitant pretreated group showed a more significant decrease in lipid peroxidation (LPO) and increased in the superoxide dismutase (SOD), catalase (CAT), glutathione (GSH) and total thiol levels as compared to ischemic reperfusion group. Histopathological damage was significantly reduced in drug treated groups as compared to ischemia-reperfusion group.
Conclusion: The findings of the present study suggest that pretreatment with piracetam and vanadyl sulfate in combination prevents the ischemia-reperfusion injury and prevented oxidative tissue damage as shown by decreased lipid peroxides, restored the antioxidant levels, histological changes such as infarct area, inflammatory changes, and edema.
2. Warlow CP. Epidemiology of stroke. Lancet 1998;352:1-4.
3. Kaul S. Stroke in India: are we different from the world? J Neurol Sci 2007;2:158-64.
4. Sethi PK. Stroke incidence in India and management of ischemic stroke. Neuroscience 2002;2:139-42.
5. Tuhrim S. Management of stroke and transient ischemic attack. Mt Sinai J Med 2002;69:121-30.
6. Cheng YD, Khoury LA. Neuroprotection for ischemic stroke: two decades of success and failure. Am Soc Exp Neurother 2005;1:36-45.
7. Adamson J, Beswick A, Ebrahim S. Is stroke the most common cause of disability? J Stroke Cerebrovascular Diseases 2004;13:171-7.
8. Gorelick P. Racial differences in ischemic cerebrovascular diseases. J Stroke Cerebrovascular Diseases 1996;6:55-9.
9. Gupta Yk, Briyal S. Animal models of cerebral ischemia for evaluation of drugs. Indian J Physiol Pharmacol 2004;48:379-94.
10. Winblad B. Piracetam: a review of pharmacological properties and clinical uses. CNS Drug Rev 2005;11:169-82.
11. Tunali S, Yanardag. Effect of vanadyl sulfate on the status of lipid parameters and on stomach and spleen tissues of streptozotocin-induced diabetic rats. Pharmacol Res 2006;53:271-7.
12. Shioda N, Ishigami T, Han F, Moriguchi S, Shibuya M, Iwabuchi Y, et al. Activation of phosphatidylinositol 3-kinase/ protein kinase B pathway by a vanadyl compound mediates its neuroprotective effect in mouse brain ischemia. J Neuropharmacol 2007;148:221-9.
13. Bhuiyan SMD, Shioda N, Fukunaga k. Targeting protein kinase B/Akt signaling with vanadium compounds for cardioprotection. Cardiovasc and Renal 2008;12:1217-27.
14. Zhi H, Liao Y, Zheng M, Zeng FD, Guo LJ. Piracetam improves cognitive deficits caused by chronic cerebral hypoperfusion in rats. Cell Mol Neurobiol 2008;28:613-27.
15. Llobet J, Domingo J. Acute toxicity of vanadium compounds in rats and mice. Toxicol Lett 1984;23:227-31.
16. Farbiszewski R, Bielawski K, Bielawska A, Sobaniec W. Spermine protects in vivo the antioxidant enzymes in transiently hypoperfused rat brain. Acta Neurobiol Exp 1995;55:253â€“8.
17. Prabhakar KR, Veerapur VP, Vipan PK, Priyadarsini KI, Rao BSS, Unnikrishnan MK. Evaluation and optimization of radioprotective activity of Coronopus didymus Linn. in irradiated mice. Int J Radiation Biol 2006;82:525â€“36.
18. Anuradha N, Chatkerjee IB. Assay of superoxide dismutase activity in animal tissues. J Biosci 1988;13:305-15.
19. Claiborne A. Catalase activity. In: Greenwald RA. Ed. CRC handbook of methods for oxygen radical research. CRC Press: Boca Raton, Florida, USA; 1995. p. 283-4.
20. Sedlak J, Lindsay RH. Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissue with Ellmanâ€™s reagent. Anal Biochem 1968;25:192-205.
21. Lowry OH, Rosebrough NJ, Fair AL, Randall RJ. Protein measurement with Folin phenol reagent. J Biol Chem 1951;193:265â€“75.
22. Leker RR, Shohami E. Cerebral ischemia and trauma-different etiologies yet similar mechanisms: neuroprotective opportunities. Brain Res Rev 2002;39:55â€“73.
23. Chandrashekhar VM, Ranpariya VL, Ganapaty S, Parashar A, Muchandi AA. Neuroprotective activity of Matricaria recutita Linn against the global model of ischemia in rats. J Ethnopharmacol 2010;127:645-51.
24. Wang Z, Liu T, Lu Gan, Wang T, Yuan X, Zhang B, et al. Shikonin protects mouse brain against cerebral ischemia/reperfusion injury through its antioxidant activity. Eur J Pharmacol 2010;643:211-7.
25. Dringer R. Metabolism and function of glutathione in brain. Prog Neurobiol 2000;62:649-71.
26. Dib M, Garrel C, Favier A, Robin V, Desnuelle C. Can malondialdehyde be used as a biological marker of progression in neurodegenerative disease? J Neurol 2002;249:367-74.